SCHEMBL7682115

SCHEMBL7682115

CCOC(=O)c1cc(-c2cccc(C)c2-c2ccccc2)[nH]c1C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MDM2 Q00987 3/20 0.50
ALDH1A1 P00352 5/20 0.49
MAPT P10636 5/20 0.49
GAA P10253 4/20 0.49
HPGD P15428 4/20 0.49
RAB9A P51151 3/20 0.49
SMN1; SMN2 Q16637 3/20 0.49
ALOX15 P16050 2/20 0.49
HSD17B10 Q99714 2/20 0.49
BRD4 O60885 5/20 0.49
LMNA P02545 2/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
PDE3B Q13370 2/20 0.46
PDE3A Q14432 2/20 0.46
TSHR P16473 1/20 0.44
NPC1 O15118 3/20 0.44
KDM4E B2RXH2 2/20 0.44
NPSR1 Q6W5P4 1/20 0.44
POLB P06746 1/20 0.44
CYP1A2 P05177 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1156069 0.84 BRD4 (0.63) MDM2ALDH1A1MAPTGAAHPGD
SCHEMBL16008336 0.78 BRD4 (0.72) ALDH1A1MAPTGAASMN1; SMN2BRD4
SCHEMBL28985324 0.77 TSHR (0.61) ALDH1A1MAPTGAAHPGDRAB9A
SCHEMBL1156780 0.74 TSHR (0.49) ALDH1A1MAPTRAB9ASMN1; SMN2HSD17B10
SCHEMBL7997890 0.74 ALDH1A1 (0.56) MDM2ALDH1A1MAPTGAAHPGD
SCHEMBL29551740 0.73 ALDH1A1 (0.52) MDM2ALDH1A1MAPTGAAHPGD
SCHEMBL375495 0.73 BRD4 (0.58) ALDH1A1MAPTRAB9ASMN1; SMN2BRD4
SCHEMBL12647490 0.72 TSHR (0.53) ALDH1A1MAPTGAAHPGDRAB9A
SCHEMBL19727271 0.72 TUBB4A (0.53) MDM2ALDH1A1MAPTGAAHPGD
SCHEMBL16042329 0.72 MAPT (0.57) ALDH1A1MAPTRAB9ASMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6372777-B1 ENZYME INHIBITORS TREATMENT OF INFLAMMATORY DISEASES AND OTHER DISEASES INVOLVING ELEVATED LEVELS OF CYTOKINES, AS WELL AS CENTRAL NERVOUS SYSTEM (CNS) DISORDERS, ICOS CORPORATION 2002-04-16 US disclosed